Professor Martin Stockler
People_

Professor Martin Stockler

MBBS(Hons) MSc(Clin Epi) FRACP
Professor of Oncology and Clinical Epidemiology
NHMRC Clinical Trials Centre
Medicine, Central Clinical School
Phone
+61 2 9562 5313
Fax
+61 2 9565 1863
Professor Martin Stockler

Martin Stockleris Professor of Oncology and Clinical Epidemiology at The University of Sydney, a consultant medical oncologist at the Concord Repatriation General Hospital and Chris O’Brien Lifehouse RPA, and Oncology Director at the NHMRC Clinical Trials Centre.

After internal medicine and medical oncology training in Sydney, Australia he spent 3 years in Toronto, Canada doing a clinical research fellowship at the Princess Margaret Hospital and a Masters in Clinical Epidemiology at the University of Toronto with Ian Tannock and Pamela Goodwin.

His research focuses on using clinical trials to improve quality of life, survival, prognostication, and doctor-patient communication for those affected by cancer, particularly from genitourinary, gynaecologic and thoracic primaries. His clinical focus is genitourinary cancers.

Improving quality of life, survival, prognostication, and doctor-patient communication for those affected by cancer, particularly genitourinary (prostate, testis, kidney, bladder), gynaecologic (ovary, endometrium, cervix), and thoracic (lung and mesothelioma). Clinical trials, meta-analaysis, evidence based medicine, biostatistics.

Oncology, clinical research methods, evidence-based medicine, patient-doctor communication.

Cancer

Publications

Books

  • Chapman, S., Barratt, A., Stockler, M. (2010). Let sleeping dogs lie What men should know before getting tested for prostate cancer. Sydney: Sydney University Press.

Book Chapters

  • Butow, P., Tattersall, M., Stockler, M. (2017). Discussing prognosis and communicating risk. In D. Kissane, B. Bultz, P. Butow, C. Bylund, S. Noble & S. Wilkinson (Eds.), Oxford Textbook of Communication in Oncology and Palliative Care (Second Edition), (pp. 77-82). Oxford: Oxford University Press. [More Information]
  • Butow, P., Hagerty, R., Tattersall, M., Stockler, M. (2008). Foretelling: Communicating the prognosis. In N. Christakis and P. Glare (Eds.), Prognosis in Advanced Cancer, (pp. 33-53). Oxford: Oxford University Press.
  • Stockler, M., Duric, V., Coates, A. (2006). Patients' preferences: what makes treatments worthwhile? In Martine J. Piccart .. [et al.] (Eds.), Breast cancer and molecular medicine, (pp. 925-944). Berlin ; New York: Springer.

Journals

  • Tan, L., Brown, C., Mersiades, T., Lee, C., John, T., Kao, S., Newnham, G., O'Byrne, K., Parakh, S., Bray, V., Yip, S., Clarke, S., Pavlakis, N., Stockler, M., et al (2024). A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE. Nature Communications, 15(1). [More Information]
  • Mahon, K., De Bono, J., Chi, K., Clark, G., Breit, S., Brown, D., Horvath, L., Sutherland, S., Lin, H., Stockler, M., Gurney, H., et al (2024). Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer. The Prostate, 84(8), 747-755. [More Information]
  • Naher, S., Mercieca-Bebber, R., Siu, D., Stockler, M., Kiely, B., Grimison, P. (2024). Estimating survival scenarios in advanced or metastatic gastric and oesophageal adenocarcinoma: a systematic review of randomized-controlled trials. Current Medical Research and Opinion. [More Information]

Conferences

  • Johnson, S., Butow, P., Bell, M., Detering, K., Clayton, J., Silvester, W., Kiely, B., Clarke, S., Vaccaro, L., Stockler, M., Beale, P., Fitzgerald, N., Tattersall, M. (2017). A Randomized Controlled Trial of an Advance Care Planning Intervention for Patients with Incurable Cancer. The 44th Clinical Oncological Society of Australia Annual Scientific Meeting,.
  • Kiely, B., Lee, C., Tattersall, M., Stockler, M. (2010). How long have I got? Estimating post-progression survival after first line chemotherapy for metastatic breast cancer based on data from randomized trials. 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.
  • Kiely, B., Soon, Y., Tattersall, M., Stockler, M. (2010). How long have I got? Estimating survival for women starting first-line chemotherapy for metastatic breast cancer (MBC): A systematic review of recent randomized trials. 2010 American Society of Clinical Oncology (ASCO) Annual Meeting.

2024

  • Tan, L., Brown, C., Mersiades, T., Lee, C., John, T., Kao, S., Newnham, G., O'Byrne, K., Parakh, S., Bray, V., Yip, S., Clarke, S., Pavlakis, N., Stockler, M., et al (2024). A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE. Nature Communications, 15(1). [More Information]
  • Mahon, K., De Bono, J., Chi, K., Clark, G., Breit, S., Brown, D., Horvath, L., Sutherland, S., Lin, H., Stockler, M., Gurney, H., et al (2024). Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer. The Prostate, 84(8), 747-755. [More Information]
  • Naher, S., Mercieca-Bebber, R., Siu, D., Stockler, M., Kiely, B., Grimison, P. (2024). Estimating survival scenarios in advanced or metastatic gastric and oesophageal adenocarcinoma: a systematic review of randomized-controlled trials. Current Medical Research and Opinion. [More Information]

2023

  • Campbell, I., Wetzig, N., Ung, O., Espinoza, D., Farshid, G., Collins, J., Kollias, J., Gebski, V., Mister, R., Simes, R., Stockler, M., et al (2023). 10-Year axillary recurrence in the RACS SNAC1 randomised trial of sentinel lymph node-based management versus routine axillary lymph node dissection. Breast, 70, 70-75. [More Information]
  • John, N., Pathmanandavel, S., Crumbaker, M., Counter, W., Ho, B., Yam, A., Wilson, P., Niman, R., Ayers, M., Poole, A., Stockler, M., et al (2023). 177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy. Journal of Nuclear Medicine, 64(3), 410-415. [More Information]
  • Nahm, S., Martin, A., Clayton, J., Grimison, P., Moth, E., Pavlakis, N., Sjoquist, K., Smith-Uffen, M., Tognela, A., Vasista, A., Stockler, M., Kiely, B. (2023). Accuracy of oncologists' estimates of expected survival time in advanced cancer. JNCI Cancer Spectrum, 7(6). [More Information]

2022

  • Leighl, N., Laurie, S., Goss, G., Hughes, B., Stockler, M., Tsao, M., Hwang, D., Joubert, P., Kulkarni, S., Blais, N., et al (2022). CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC. Journal of Thoracic Oncology, 17(3), 434-445. [More Information]
  • Farrell, R., Burling, M., Lee, C., Pather, S., Robledo, K., Mercieca-Bebber, R., Stockler, M. (2022). Clinical trial protocol for HyNOVA: Hyperthermic and normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage iii epithelial ovarian, fallopian tube and primary peritoneal cancer (ANZGOG1901/2020). Journal of Gynecologic Oncology, 33(1), e1. [More Information]
  • Mak, B., Lin, H., Kwan, E., Fettke, H., Tran, B., Davis, I., Mahon, K., Stockler, M., Briscoe, K., Marx, G., Hoy, A., Horvath, L., et al (2022). Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer. BMC Medicine, 20(1), 112-1-112-14. [More Information]

2021

  • Hofman, M., Emmett, L., Sandhu, S., Iravani, A., Joshua, A., Goh, J., Pattison, D., Tan, T., Kirkwood, I., Ng, S., Guminski, A., Zhang, A., Stockler, M., Martin, A., et al (2021). [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. The Lancet, 397(10276), 797-804. [More Information]
  • Mitchell, P., O'Byrne, K., Stockler, M., Yip, S., nhmrWalker, M., Balasubramaniam, S., Ab Rahman, A., Kok, P., Jurkovic, H., Brown, C., et al (2021). A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiotherapy (SABR) in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD). International Journal of Radiation Oncology Biology Physics, 111(3), S10-S11. [More Information]
  • Livingstone (nee Ratcliffe), A., Dempsey, K., Stockler, M., Howard, K., Long, G., Carlino, M., Menzies, A., Morton, R. (2021). Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews. BMC Cancer, 21(1), 1014. [More Information]

2020

  • Eisen, T., Frangou, E., Oza, B., Ritchie, A., Smith, B., Kaplan, R., Davis, I., Stockler, M., Albiges, L., Escudier, B., et al (2020). Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: Results from the SORCE randomized phase III intergroup trial. Journal of Clinical Oncology, 38(34), 4064-4075. [More Information]
  • Stockler, M. (2020). ASCO updated recommendations for preventing and treating VTE in adults with cancer. Annals of Internal Medicine, 172(2), JC2. [More Information]
  • Vasista, A., Stockler, M., Martin, A., Lawrence, N., Kiely, B. (2020). Communicating prognostic information: what do oncologists think patients with incurable cancer should be told? Internal Medicine Journal, 50(12), 1492-1499. [More Information]

2019

  • Kiely, B., Stockler, M. (2019). Accentuating the Positive: Do Trials Give Unrealistic Expectations of Long-Term Survival? JNCI Cancer Spectrum, 3(2), 1-2. [More Information]
  • Vasista, A., Stockler, M., Martin, A., Pavlakis, N., Sjoquist, K., Goldstein, D., Gill, S., Jain, V., Liu, G., Kannourakis, G., Kiely, B., et al (2019). Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in Advanced Gastric Cancer. The Oncologist, 24(11), e1102-e1107. [More Information]
  • Chim, L., Salkeld, G., Kelly, P., Lipworth, W., Hughes, D., Stockler, M. (2019). Community views on factors affecting medicines resource allocation: Cross-sectional survey of 3080 adults in Australia. Australian Health Review, 43(3), 254-260. [More Information]

2018

  • Johnson, S., Butow, P., Bell, M., Detering, K., Clayton, J., Silvester, W., Kiely, B., Clarke, S., Vaccaro, L., Stockler, M., Tattersall, M., et al (2018). A randomised controlled trial of an advance care planning intervention for patients with incurable cancer. British Journal of Cancer, 119(10), 1182-1190. [More Information]
  • Tran, A., Fogarty, G., Nowak, A., Espinoza, D., Rowbotham, N., Stockler, M., Morton, R. (2018). A systematic review and meta-analysis of utility estimates in melanoma. British Journal of Dermatology, 178(2), 384-393. [More Information]
  • Smith, B., Rutherford, C., Butow, P., Olver, I., Luckett, T., Grimison, P., Toner, G., Stockler, M., King, M. (2018). A systematic review of quantitative observational studies investigating psychological distress in testicular cancer survivors. Psycho-Oncology, 27(4), 1129-1137. [More Information]

2017

  • Lin, H., Mahon, K., Weir, J., Mundra, P., Spielman, C., Briscoe, K., Gurney, H., Mallesara, G., Marx, G., Stockler, M., Hoy, A., Horvath, L., et al (2017). A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer. International Journal of Cancer, 141(10), 2112-2120. [More Information]
  • Johnson, S., Butow, P., Bell, M., Detering, K., Clayton, J., Silvester, W., Kiely, B., Clarke, S., Vaccaro, L., Stockler, M., Beale, P., Fitzgerald, N., Tattersall, M. (2017). A Randomized Controlled Trial of an Advance Care Planning Intervention for Patients with Incurable Cancer. The 44th Clinical Oncological Society of Australia Annual Scientific Meeting,.
  • Mercieca-Bebber, R., Friedlander, M., Calvert, M., Stockler, M., Kyte, D., Kok, P., King, M. (2017). A systematic evaluation of compliance and reporting of patient-reported outcome endpoints in ovarian cancer randomised controlled trials: implications for generalisability and clinical practice. Journal of Patient-Reported Outcomes, 1, 1-10. [More Information]

2016

  • Johnson, S., Clayton, J., Butow, P., Silvester, W., Detering, K., Hall, J., Kiely, B., Cebon, J., Clarke, S., Bell, M., Stockler, M., Tattersall, M., et al (2016). Advance care planning in patients with incurable cancer: Study protocol for a randomised controlled trial. BMJ Open, 6(12), 1-10. [More Information]
  • Dong, S., Butow, P., Agar, M., Lovell, M., Boyle, F., Stockler, M., Forster, B., Jaure, A. (2016). Clinicians' Perspectives on Managing Symptom Clusters in Advanced Cancer: A Semistructured Interview Study. Journal of Pain and Symptom Management, 51(4), 706-717.e5. [More Information]
  • Mercieca-Bebber, R., Palmer, M., Brundage, M., Calvert, M., Stockler, M., King, M. (2016). Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: A systematic review. BMJ Open, 6(6), 1-47. [More Information]

2015

  • Davidson, A., Veillard, A., Tognela, A., Chan, M., Huighes, B., Boyer, M., Briscoe, K., Begbie, S., Abdi, E., Crombie, C., Chinchen, S., Espinoza, D., Coskinas, X., Pavlakis, N., Stockler, M., et al (2015). A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial. Annals of Oncology, 26(11), 2280-2286. [More Information]
  • Sundaresan, P., King, M., Stockler, M., Costa, D., Milross, C. (2015). Barriers to radiotherapy utilisation in New South Wales Australia: Health professionals' perceptions of impacting factors. Journal of Medical Imaging and Radiation Oncology, 59(4), 535-541. [More Information]
  • Hayne, D., Stockler, M., McCombie, S., Chalasani, V., Long, A., Martin, A., Sengupta, S., Davis, I. (2015). BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301). BMC Cancer, 15(1), 1-7. [More Information]

2014

  • Grimison, P., Stockler, M., Chatfield, M., Thomson, D., Gebski, V., Friedlander, M., Boland, A., Houghton, B., Gruney, H., Rosenthal, M., et al (2014). Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Annals of Oncology, 25(1), 143-148. [More Information]
  • Lin, H., Castillo, L., Mahon, K., Chiam, K., Lee, B., Nguyen, Q., Boyer, M., Stockler, M., Pavlakis, N., Marx, G., Gurney, H., Horvath, L., et al (2014). Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. British Journal of Cancer, 110(10), 2462-2471. [More Information]
  • Ellis, P., Shepherd, F., Millward, M., Perrone, F., Seymour, L., Liu, G., Sun, S., Cho, B., Morabito, A., Leighl, N., Stockler, M., et al (2014). Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. The Lancet Oncology, 15(12), 1379-1388. [More Information]

2013

  • Nowak, A., Brown, C., Millward, M., Creaney, J., Byrne, M., Hughes, B., Kremmidiotis, G., Bibby, D., Leske, A., Mitchell, P., Pavlakis, N., Stockler, M., et al (2013). A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. Lung Cancer, 81(3), 422-427. [More Information]
  • McCaughan, G., Blinman, P., Boyer, M., Stockler, M. (2013). Better estimates of survival for patients considering adjuvant chemotherapy after surgery for early non-small-cell lung cancer. Internal Medicine Journal, 43(4), 424-429. [More Information]
  • Gzell, C., Kench, J., Stockler, M., Hruby, G. (2013). Biopsy-proven brain metastases from prostate cancer: a series of four cases with review of the literature. International Urology and Nephrology, 45(3), 735-742. [More Information]

2012

  • Wong, M., Stockler, M., Pavlakis, N. (2012). Bisphosphonates and other bone agents for breast cancer (Review). The Cochrane Library Chichester UK: John Wiley and Sons Ltd, 2, 1-136. [More Information]
  • Kiely, B., Alam, M., Blinman, P., Tattersall, M., Stockler, M. (2012). Estimating typical, best-case and worst-case life expectancy scenarios for patients starting chemotherapy for advanced non-small-cell lung cancer: A systematic review of contemporary randomized trials. Lung Cancer, 77(3), 537-544. [More Information]
  • Wilcken, N., Stockler, M. (2012). Individual patient meta-analysis: Taxane plus anthracycline reduces mortality from early breast cancer. Annals of Internal Medicine, 156(12), 432-444. [More Information]

2011

  • Lee, C., Hudson, M., Stockler, M., Coates, A., Ackland, S., Gebski, V., Lord, S., Friedlander, M., Boyle, F., Simes, R. (2011). A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer. Breast Cancer Research and Treatment, 129(2), 467-476. [More Information]
  • Stockler, M., Harvey, V., Francis, P., Byrne, M., Ackland, S., Fitzharris, B., Van Hazel, G., Wilcken, N., Grimison, P., Nowak, A., Zannino, D., Gebski, V., Coates, A., et al (2011). Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer. Journal of Clinical Oncology, 29(34), 4498-4504. [More Information]
  • Gennari, A., Stockler, M., Puntoni, M., Sormani, M., Nanni, O., Amadori, D., Wilcken, N., D'Amico, M., DeCensi, A., Bruzzi, P. (2011). Duration of Chemotherapy for Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Journal of Clinical Oncology, 29(16), 2144-2149. [More Information]

2010

  • Moore, M., Stockler, M., Lim, R., Mok, T., Millward, M., Boyer, M. (2010). A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group. Cancer Chemotherapy and Pharmacology, 66(5), 845-850. [More Information]
  • Lovell, M., Forder, P., Stockler, M., Butow, P., Briganti, E., Chye, R., Goldstein, D., Boyle, F. (2010). A Randomized Controlled Trial of a Standardized Educational Intervention for Patients with Cancer Pain. Journal of Pain and Symptom Management, 40(1), 49-59. [More Information]
  • Blinman, P., Duric, V., Nowak, A., Beale, P., Clarke, S., Briscoe, K., Boyce, A., Goldstein, D., Hudson, M., Stockler, M. (2010). Adjuvant chemotherapy for early colon cancer: What survival benefits make it worthwhile? European Journal of Cancer, 46(10), 1800-1807. [More Information]

2009

  • Grimison, P., Simes, R., Hudson, M., Stockler, M. (2009). Deriving a Patient-Based Utility Index from a Cancer-Specific Quality of Life Questionnaire. Value in Health, 12(5), 800-807. [More Information]
  • Soon, Y., Stockler, M., Askie, L., Boyer, M. (2009). Duration of Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Trials. Journal of Clinical Oncology, 27(20), 3277-3283. [More Information]
  • Zhao, L., Lee, B., Brown, D., Molloy, M., Marx, G., Pavlakis, N., Boyer, M., Stockler, M., Kaplan, W., Breit, S., et al (2009). Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Research, 69(19), 7696-7703. [More Information]

2008

  • Nowak, A., Cebon, J., Hargreaves, C., Dhillon, H., Findlay, M., Gebski, V., Stockler, M. (2008). Assessment of health-related quality of life and patient benefit as outcome measures for clinical trials in hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology, 4, 55-67. [More Information]
  • Smith, M., Gill, P., Wetzig, N., Sourjina, T., Gebski, V., Ung, O., Campbell, I., Kollias, J., Coskinas, X., Macphee, A., Simes, R., Stockler, M., et al (2008). Comparing patients' and clinicians' assessment of outcomes in a randomised trial of sentinel node biopsy for breast cancer (the RACS SNAC trial). Breast Cancer Research and Treatment, 117(1), 99-109. [More Information]
  • Duric, V., Butow, P., Sharpe, L., Heritier, S., Boyle, F., Beith, J., Wilcken, N., Coates, A., Simes, R., Stockler, M. (2008). Comparing patients' and their partners' preferences for adjuvant chemotherapy in early breast cancer. Patient Education and Counseling, 72(2), 239-245. [More Information]

2007

  • Smith, M., Gill, P., Wetzig, N., Sourjina, T., Simes, R., Stockler, M. (2007). Bs06 patient-rated outcome measures were more sensitive than clinician-rated measures at distinguishing the effects of sentinel node biopsy and axillary clearance in the snac trial. ANZ Journal of Surgery, 77(Suppl. 1), A2-A2. [More Information]
  • Grimison, P., Simes, R., Stockler, M. (2007). Development and validation of optimally weighted measures of global health-related quality of life (QoL) and utility based on a cancer-specific QoL instrument. Value in Health, 10(6), A226-A227.
  • Stockler, M., O'Connell, R., Nowak, A., Goldstein, D., Turner, J., Wilcken, N., Wyld, D., Abdi, E., Glasgow, A., Beale, P., Dhillon, H., Heritier, S., Carter, C., Hickie, I., Simes, R., et al (2007). Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. The Lancet Oncology, 8(7), 603-612. [More Information]

2006

  • Stockler, M., Sourjina, T., Harvey, V., Frances, P., Byrne, M., van Hazel, G., Fitzharris, B., Ackland, S., Finch, K., Lindsay, D., Gebski, V., Simes, R., Coates, A., et al (2006). A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment. Breast Cancer Research and Treatment, 100(Supplement 1), S278-S278.
  • Pavlakis, N., Patel, D., Stockler, M. (2006). Biphosphonates in early prostate cancer. Cochrane Database of Systematic Reviews, 4, CD006249.
  • Stockler, M., Tattersall, M., Boyer, M., Clarke, S., Beale, P., Simes, R. (2006). Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer. British Journal of Cancer, 94(2), 208-212. [More Information]

2005

  • Koczwara, B., Tattersall, M., Barton, M., Coventry, B., Dewar, J., Millar, J., Olver, I., Schwarz, M., Starmer, D., Turner, D., Stockler, M. (2005). Achieving equal standards in medical student education: is a national exit examination the answer? Medical Journal of Australia, 182(5), 228-230. [More Information]
  • Joshua, A., Celermajer, D., Stockler, M. (2005). Beauty is in the eye of the examiner: reaching agreement about physical signs and their value. Internal Medicine Journal, 35(3), 178-187. [More Information]
  • Pavlakis, N., Schmidt, R., Stockler, M. (2005). Bisphosphonates for breast cancer. Cochrane Database of Systematic Reviews, 0(3), CD003474. [More Information]

2004

  • Cox, K., O'Connell, R., Stockler, M., Boyer, M., Beale, P., Simes, R. (2004). A randomized crossover trial of giving high-dose cisplatin with or without an overnight stay in hospital: Patients' preferences, quality of life, safety and resource use. Journal of Clinical Oncology, 22(14S), 547S-547S.
  • Stockler, M., Vardy, J., Pillai, A., Warr, D. (2004). Acetaminophen (Paracetamol) Improves Pain And Well-Being In People With Advanced Cancer Already Receiving A Strong Opioid Regimen: A Randomized, Double-Blind, Placebo-Controlled Cross-Over Trial. Journal of Clinical Oncology, 22(16), 3389-3394. [More Information]
  • Nowak, A., Stockler, M., Byrne, M. (2004). Assessing Quality Of Life During Chemotherapy For Pleural Mesothelioma: Feasibility, Validity, And Results Of Using The European Organization For Research And Treatment Of Cancer Core Quality Of Life Questionnaire And Lung Cancer Module. Journal of Clinical Oncology, 22(15), 3172-3180. [More Information]

2003

  • Pavlakis, N., Stockler, M. (2003). Bisphosphonates for breast cancer. Cochrane Database of Systematic Reviews, 11.
  • Stockler, M., Wilcken, N., Coates, A. (2003). Chemotherapy for advanced breast cancer- how long should it continue? Breast Cancer Research and Treatment, 81(Suppl 1), S49-S52.
  • Beslija, S., Bonneterre, J., Burstein, H., Gnant, M., Goodwin, P., Heinemann, V., Jassem, J., Köstler, W., Krainer, M., Menard, S., Stockler, M., et al (2003). Consensus on medical treatment of metastatic breast cancer. Breast Cancer Research and Treatment, 81(Supplement 1), S1-S7.

2002

  • Boyer, M., Stockler, M., Rosenthal, M., Eisinger, D., Goad, J., Webb, D. (2002). Adjuvant mitoxantrone chemotherapy for men at high risk of relapse following radical prostatectomy: a pilot study. UroOncology, 2(1), 15-17. [More Information]
  • Pavlakis, N., Stockler, M. (2002). Bisphosphonates in breast cancer. Cochrane Database of Systematic Reviews, , 1-28.
  • Wetzig, N., Gill, P., Ung, O., Collins, J., Kollias, J., Gillette, D., Gebski, V., Greig, C., Ray, A., Stockler, M. (2002). Eligibility and Choice in the royal Australiasian College of Surgeons "SNAC Trial" of Sentinel Node Biopsy versus axillary clearance in operable breast cancer. 3rd International Sentinel Node Congress.

2001

  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Henderson, I., Basser, R., Brunswick, C., Fossati, C., Liberati, A., et al (2001). Addition of drug/s to a chemotherapy regimen for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Ghersi, D., Simes, R., Stockler, M., Tattersall, M., Wilcken, N., Basser, R., Henderson, I., Brunswick, C., Fossati, R., Liberati, A., et al (2001). Antitumor antibiotic containing regimins for metastatic breast cancer [protocol]. Cochrane Database of Systematic Reviews, Issue 4, 1-4.
  • Craig, J., Irwig, L., Stockler, M., Barratt, A., Cumming, R., Caplehorn, J. (2001). Clinical epidemiology education: to help culture change now and generate new research later. 4th International Conference on the Scientific Basis of Health Services.

2000

  • Stockler, M., Wilcken, N., Ghersi, D., Simes, R. (2000). Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treatment Reviews, 26(3), 151-168. [More Information]

Selected Grants

2024

  • P3BEP Trial - Accelerating First-Line Chemotherapy to Improve Cure Rates for Advanced Germ Cell Tumours - An Australian-Led, International Randomised Trial, Grimison P, Stockler M, Martin A, National Health and Medical Research Council (NHMRC)/Clinical Trials and Cohort Studies

2022

  • Clinical development of a self-amplifying pan-tumour theranostic, Hogg P, Simes R, Codd R, Scott A, Barrington S, Stockler M, Ho Shon I, Gebski V, Goldstein D, Thompson S, Cancer Institute NSW/Translational Program Grant